However, despite its advantages, there are also considerations that researchers must keep in mind when using isoflurane anesthesia in mice. One of the primary concerns is the potential for respiratory depression. Isoflurane, like other anesthetic agents, can suppress spontaneous ventilation. Therefore, it is vital to carefully monitor respiratory rates and ensure that the inhaled concentrations are kept within safe parameters to avoid hypoxia.
The clinical trial phase is a critical milestone in drug development. Phase I trials focus on the safety of the drug and its pharmacokinetics in healthy volunteers. Phase II studies evaluate efficacy and side effects in a larger patient population. Finally, Phase III trials confirm the drug's effectiveness in diverse groups, leading to a comprehensive understanding of its therapeutic profile. Throughout these trials, the API's performance is meticulously monitored to ensure that it meets predefined efficacy and safety benchmarks.